TradingKey

關於 Syndax Pharmaceuticals Inc 公司

Syndax Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發癌症療法。其候選產品包括 revumenib 和 axatilimab。該公司正在開發 revumenib，這是一種強效、選擇性、小分子抑制劑，可抑制 menin-MLL 結合相互作用，用於治療 KMT2A 重排（也稱爲混合譜系白血病重排）、急性白血病（包括急性淋巴細胞白血病和急性髓細胞白血病 (AML)）和核磷蛋白 1（也稱爲 NPM1，突變體 A）。該公司還在探索使用 revumenib 治療實體瘤，特別是其在轉移性結直腸癌中的活性。該公司還在開發 axatilimab，這是一種單克隆抗體，可阻斷慢性移植物抗宿主病 (cGVHD) 以及特發性肺纖維化中的集落刺激因子 1 受體 (CSF-1R)。 Entinostat 是一種口服小分子候選產品，對癌細胞和免疫調節細胞有直接作用。

公司簡介

公司代碼SNDX

公司名稱Syndax Pharmaceuticals Inc

上市日期Mar 03, 2016

CEOMr. Michael A. Metzger

員工數量270

證券類型Ordinary Share

年結日Mar 03

公司地址730 Third Avenue

城市NEW YORK

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編10017

電話17814191400

網址https://syndax.com/

公司代碼SNDX

上市日期Mar 03, 2016

CEOMr. Michael A. Metzger

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Michael A. Metzger

Chief Executive Officer, Director

298.66K

-2.46%

Mr. Dennis G. Podlesak

Independent Chairman of the Board

127.33K

-11.16%

Mr. Keith A. Katkin, CPA

Independent Director

75.00K

+15.38%

Mr. Steven (Steve) Closter

Chief Commercial Officer

70.90K

--

Mr. Pierre Legault, CPA

Independent Director

65.00K

-10.96%

Nicholas A.J. Botwood ,

Head - Research and Development, Chief Medical Officer

--

Ms. Jennifer A. Jarrett

Independent Director

--

Dr. Aleksandra Rizo, M.D., Ph.D.

Independent Director

--

Mr. Keith A. Goldan, CPA

Chief Financial Officer

--

Dr. Martin H. Huber, M.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Michael A. Metzger

Chief Executive Officer, Director

298.66K

-2.46%

Mr. Dennis G. Podlesak

Independent Chairman of the Board

127.33K

-11.16%

Mr. Keith A. Katkin, CPA

Independent Director

75.00K

+15.38%

Mr. Steven (Steve) Closter

Chief Commercial Officer

70.90K

--

Mr. Pierre Legault, CPA

Independent Director

65.00K

-10.96%

Nicholas A.J. Botwood ,

Head - Research and Development, Chief Medical Officer

--

收入明細

暫無數據

暫無數據

業務

地區

暫無數據

股東統計

更新時間: 5月17日週六

持股股東

股東類型

持股股東

佔比

Kynam Capital Management LP

9.90%

BlackRock Institutional Trust Company, N.A.

7.92%

The Vanguard Group, Inc.

5.64%

Eversept Partners, LP

4.90%

Point72 Asset Management, L.P.

4.66%

Other

66.98%

持股股東

佔比

Kynam Capital Management LP

9.90%

BlackRock Institutional Trust Company, N.A.

7.92%

The Vanguard Group, Inc.

5.64%

Eversept Partners, LP

4.90%

Point72 Asset Management, L.P.

4.66%

Other

66.98%

股東類型

持股股東

佔比

Hedge Fund

54.88%

Investment Advisor

31.18%

Investment Advisor/Hedge Fund

18.83%

Research Firm

9.33%

Venture Capital

4.95%

Individual Investor

1.31%

Pension Fund

0.80%

Sovereign Wealth Fund

0.48%

Bank and Trust

0.32%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

452

105.51M

122.62%

-9.86M

2025Q1

465

105.51M

122.65%

-11.55M

2024Q4

466

101.18M

117.63%

-2.44M

2024Q3

454

91.99M

107.96%

-12.90M

2024Q2

424

90.42M

106.49%

-16.61M

2024Q1

417

93.25M

109.83%

-11.76M

2023Q4

407

91.08M

107.54%

+9.06M

2023Q3

394

77.71M

113.61%

-12.98M

2023Q2

385

77.69M

113.93%

-12.13M

2023Q1

384

79.89M

118.60%

-9.29M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Kynam Capital Management LP

8.52M

9.9%

--

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.81M

7.92%

-562.84K

-7.63%

Mar 31, 2025

The Vanguard Group, Inc.

4.86M

5.64%

-10.90K

-0.22%

Mar 31, 2025

Eversept Partners, LP

4.21M

4.9%

+3.87M

+1126.64%

Mar 31, 2025

Point72 Asset Management, L.P.

4.01M

4.66%

+2.09M

+109.25%

Mar 31, 2025

State Street Global Advisors (US)

3.97M

4.62%

+54.22K

+1.38%

Mar 31, 2025

Goldman Sachs & Company, Inc.

3.46M

4.02%

-2.08M

-37.54%

Mar 31, 2025

Citadel Advisors LLC

2.91M

3.39%

+1.83M

+167.47%

Mar 31, 2025

BofA Global Research (US)

2.87M

3.34%

+2.63M

+1069.41%

Mar 31, 2025

Sofinnova Investments, Inc

2.28M

2.64%

+1.62M

+245.45%

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

Tema Oncology ETF

0.92%

Virtus LifeSci Biotech Clinical Trials ETF

0.79%

SPDR S&P Biotech ETF

0.3%

Simplify Health Care ETF

0.18%

Direxion Daily S&P Biotech Bull 3X Shares

0.17%

Inspire Small/Mid Cap ESG ETF

0.15%

ProShares Ultra Nasdaq Biotechnology

0.09%

Invesco Nasdaq Biotechnology ETF

0.09%

iShares Biotechnology ETF

0.08%

Nuveen ESG Small-Cap ETF

0.08%

Tema Oncology ETF

佔比0.92%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.79%

SPDR S&P Biotech ETF

佔比0.3%

Simplify Health Care ETF

佔比0.18%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.17%

Inspire Small/Mid Cap ESG ETF

佔比0.15%

ProShares Ultra Nasdaq Biotechnology

佔比0.09%

Invesco Nasdaq Biotechnology ETF

佔比0.09%

iShares Biotechnology ETF

佔比0.08%

Nuveen ESG Small-Cap ETF

佔比0.08%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Syndax Pharmaceuticals Inc

9.947USD

Syndax Pharmaceuticals Inc

9.947

概覽

公司

財務